|
|
|
| Clinical effect of Repaglinide combined with Metformin on the treatment of sulfonylurea secondary failure diabetes |
| WANG Xiao-xia |
| Department of Internal Medicine,Taixing Chinese Medicine Hospital,Jiangsu Province,Taixing 225400,China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Repaglinide combined with Metformin on the treatment of sulfonylurea secondary failure diabetes.Methods Fifty patients with sulfonylurea secondary failure diabetes admitted to our hospital from May 2016 to May 2018 were enrolled as the study subjects.They were divided into control group(25 cases) and observation group (25 cases) according to random number table method.Patients in the control group were treated with Metformin on the basis of sulfonylureas,and patients in the observation group were treated with Repaglinide and Metformin.The blood glucose control effect and adverse reactions were compared between the two groups.Results There were no significant differences in the levels of fasting plasma glucose (FPG),blood sugar 2 hours after meal(2 h PG) and glycosylated hemoglobin (HbA1c) between the two groups before treatment (P>0.05).The FPG and 2 h PG levels in the two groups after treatment for 3,6,and 12 weeks were lower than those before treatment,with statistical significance (P<0.01).The HbA1c levels in the two groups after 6 and 12 weeks of treatment were lower than those before treatment,the differences were statistically significant (P<0.05).The levels of FPG and HbA1c in the observation group were lower than those in the control group after 6 and 12 weeks of treatment,the differences were statistically significant (P<0.05).The 2 h PG levels in the observation group were lower than those in the control group after 3,6,and 12 weeks of treatment,the differences were statistically significant (P<0.01 ).The insulin (INS) levels after treatment in both groups were lower than those before treatment,and the C-peptide (CP) levels were higher than those before treatment,the differences were statistically significant (P<0.05).The INS level of the patients in the observation group after treatment was lower than that in the control group,and the CP level was higher than that in the control group,the differences were statistically significant (P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant (P<0.05).Conclusion The combination of Repaglinide and Metformin on the treatment of sulfonylurea secondary failure diabetes patients has better blood sugar control effect and better adverse reaction improvement,which is worthy of promotion.
|
|
|
|
|
|
| [1] |
付欢欢，余苏萍.肛肠术后尿潴留的中西医治疗进展[J].现代中西医结合杂志，2016，25（17）：1927-1930.
|
| [2] |
余细珍.瑞格列奈联合二甲双胍对于2型糖尿病患者的治疗效果分析[J].湖北科技学院学报（医学版），2017，31（5）：399-401.
|
| [3] |
王华.瑞格列奈片、二甲双胍联合步行锻炼对社区2型糖尿病患者血脂代谢的影响[J].国际医药卫生导报，2016，22（16）：2502-2504.
|
| [4] |
单留峰，郭丽芳.益气养阴活血化瘀法治疗2型糖尿病临床研究[J].中医学报，2016，31（5）：663-666.
|
| [5] |
黄碧波，宗晓敏.瑞格列奈与二甲双胍治疗2型糖尿病的临床疗效分析[J].家庭医药，2017，（5）：114.
|
| [6] |
蒋黎，严熙.瑞格列奈与二甲双胍治疗继发性失效2型糖尿病的临床效果观察[J].中外医学研究，2018，16（18）：27-29.
|
| [7] |
刘蕾.瑞格列奈片联合二甲双胍治疗妊娠期糖尿病的疗效[J].川北医学院学报，2019，34（1）：85-87，154.
|
| [8] |
苏青.二甲双胍降糖作用的分子机制[J].中华内分泌代谢杂志，2016，32（9）：716-722.
|
| [9] |
孙丽云，陈刚，张顺康，等.二甲双胍对不同雌激素受体状态乳腺癌细胞的放射增敏作用及其机制研究[J].中华放射医学与防护杂志，2018，38（5）：327-334.
|
| [10] |
曹华祥，黄驰，杨力，等.二甲双胍对胃癌细胞SGC7901和BGC823生长的影响及其机制[J].中华实验外科杂志，2017，34（10）：1691-1694.
|
| [11] |
杨明峰，丁瑜，王艺文，等.二甲双胍通过腺苷酸活化蛋白酶-哺乳动物雷帕霉素靶蛋白信号通路调节胶原诱导性关节炎大鼠辅助性T细胞17/调节性T 细胞的分化及细胞因子的表达[J].中华风湿病学杂志，2016，20（9）：614-618.
|
| [12] |
周月，孔姿莉，王翔，等.二甲双胍缓释片与普通片对2型糖尿病患者胃肠道副作用的风险比较：Meta分析[J].中华糖尿病杂志，2019，11（1）：32-39.
|
| [13] |
李天艺，李华，焦文君，等.二甲双胍对老年2型糖尿病炎症和肠道菌群失衡的临床疗效研究[J].中华老年医学杂志，2018，37（8）：879-882.
|
| [14] |
王晔，熊咏超，薛少博，等.二甲双胍对大鼠放射性肺纤维化的防治作用机制[J].中华放射医学与防护杂志，2017，37（10）：736-741.
|
| [15] |
刘伟，杨明兰.重新认识二甲双胍在多囊卵巢综合征代谢调节中的作用及机制[J].中华糖尿病杂志，2018，10（10）：685-687.
|
|
|
|
